BioMarin Pharmaceutical Inc
BMRN61.150USD
+9.200+17.71%
終値 12/19, 16:00（ET）15分遅れの株価
11.75B時価総額
22.49直近12ヶ月PER
詳細情報 BioMarin Pharmaceutical Inc 企業名
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
BioMarin Pharmaceutical Incの企業情報
企業コードBMRN
会社名BioMarin Pharmaceutical Inc
上場日Jul 23, 1999
最高経営責任者「CEO」Hardy (Alexander)
従業員数3040
証券種類Ordinary Share
決算期末Jul 23
本社所在地770 Lindaro Street
都市SAN RAFAEL
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号94901
電話番号14155066700
ウェブサイトhttps://www.biomarin.com/
企業コードBMRN
上場日Jul 23, 1999
最高経営責任者「CEO」Hardy (Alexander)
BioMarin Pharmaceutical Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Richard A. (Randy) Meier
Mr. Richard A. (Randy) Meier
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
120.34K
+5.85%
Mr. Alexander Hardy
Mr. Alexander Hardy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
46.80K
-26.15%
Dr. Gregory R Friberg, M.D.
Dr. Gregory R Friberg, M.D.
Executive Vice President, Chief Research & Development Officer
Executive Vice President, Chief Research & Development Officer
43.51K
-7.06%
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Independent Director
Independent Director
37.15K
+21.80%
Ms. Cristin Hubbard
Ms. Cristin Hubbard
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
30.55K
-7.36%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
23.29K
+39.97%
Dr. Athena M. Countouriotis, M.D.
Dr. Athena M. Countouriotis, M.D.
Independent Director
Independent Director
8.83K
+305.05%
Ms. Barbara W. Bodem
Ms. Barbara W. Bodem
Independent Director
Independent Director
8.83K
+305.05%
Ms. Elizabeth Mckey Anderson
Ms. Elizabeth Mckey Anderson
Independent Director
Independent Director
--
--
Mr. Timothy Walbert
Mr. Timothy Walbert
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Richard A. (Randy) Meier
Mr. Richard A. (Randy) Meier
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
120.34K
+5.85%
Mr. Alexander Hardy
Mr. Alexander Hardy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
46.80K
-26.15%
Dr. Gregory R Friberg, M.D.
Dr. Gregory R Friberg, M.D.
Executive Vice President, Chief Research & Development Officer
Executive Vice President, Chief Research & Development Officer
43.51K
-7.06%
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Independent Director
Independent Director
37.15K
+21.80%
Ms. Cristin Hubbard
Ms. Cristin Hubbard
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
30.55K
-7.36%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
23.29K
+39.97%
収益内訳
通貨: USD更新時刻: Mon, Oct 6
通貨: USD更新時刻: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
事業別USD
会社名
収益
比率
Voxzogo
221.39M
27.23%
Vimizim
215.42M
26.50%
Naglazyme
128.87M
15.85%
Palynziq
105.94M
13.03%
Aldurazyme
56.44M
6.94%
他の
84.92M
10.45%
地域別USD
会社名
収益
比率
United States
272.55M
33.53%
Europe
243.14M
29.91%
Rest of the world
142.74M
17.56%
Latin America
98.12M
12.07%
ALDURAZYME net product revenues marked by Sanofi
56.44M
6.94%
事業別
地域別
事業別USD
会社名
収益
比率
Voxzogo
221.39M
27.23%
Vimizim
215.42M
26.50%
Naglazyme
128.87M
15.85%
Palynziq
105.94M
13.03%
Aldurazyme
56.44M
6.94%
他の
84.92M
10.45%
株主
更新時刻: Sun, Nov 16
更新時刻: Sun, Nov 16
株主統計
種類
株主統計
株主統計
比率
The Vanguard Group, Inc.
9.63%
BlackRock Institutional Trust Company, N.A.
8.98%
PRIMECAP Management Company
7.93%
Dodge & Cox
7.64%
State Street Investment Management (US)
4.56%
他の
61.26%
株主統計
株主統計
比率
The Vanguard Group, Inc.
9.63%
BlackRock Institutional Trust Company, N.A.
8.98%
PRIMECAP Management Company
7.93%
Dodge & Cox
7.64%
State Street Investment Management (US)
4.56%
他の
61.26%
種類
株主統計
比率
Investment Advisor
46.12%
Investment Advisor/Hedge Fund
37.47%
Hedge Fund
6.71%
Pension Fund
3.35%
Sovereign Wealth Fund
1.40%
Research Firm
1.35%
Bank and Trust
1.06%
Individual Investor
0.74%
Venture Capital
0.35%
他の
1.43%
機関投資家保有株
更新時刻: Mon, Dec 8
更新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
1296
187.90M
108.82%
+71.66K
2025Q3
1334
187.86M
111.13%
-2.15M
2025Q2
1344
190.17M
114.04%
-8.63M
2025Q1
1331
198.83M
113.78%
-19.35M
2024Q4
1317
196.49M
110.91%
+4.70M
2024Q3
1283
191.71M
111.61%
-4.43M
2024Q2
1271
195.66M
108.22%
+2.33M
2024Q1
1257
193.46M
109.63%
-14.58M
2023Q4
1275
195.75M
103.93%
+7.49M
2023Q3
1255
188.56M
102.57%
+2.75M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
The Vanguard Group, Inc.
18.91M
9.85%
-8.07K
-0.04%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
18.04M
9.39%
-79.52K
-0.44%
Jun 30, 2025
PRIMECAP Management Company
15.77M
8.21%
-2.00M
-11.26%
Jun 30, 2025
Dodge & Cox
15.11M
7.87%
+153.07K
+1.02%
Jun 30, 2025
State Street Investment Management (US)
8.85M
4.61%
+384.66K
+4.55%
Jun 30, 2025
Viking Global Investors LP
12.29M
6.4%
+1.49M
+13.78%
Jun 30, 2025
AQR Capital Management, LLC
5.58M
2.91%
+2.65M
+90.74%
Jun 30, 2025
Geode Capital Management, L.L.C.
3.47M
1.81%
+43.19K
+1.26%
Jun 30, 2025
Millennium Management LLC
2.83M
1.48%
+2.16M
+319.74%
Jun 30, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
First Trust NYSE Arca Biotechnology Index Fund
3.44%
Global X Genomics & Biotechnology ETF
2.98%
Invesco Biotechnology & Genome ETF
2.47%
First Trust Health Care Alphadex Fund
2.15%
Goldman Sachs Future Health Care Equity ETF
2.15%
State Street SPDR S&P Biotech ETF
1.93%
WealthTrust DBS Long Term Growth ETF
1.86%
Alger Russell Innovation ETF
1.84%
Virtus LifeSci Biotech Products ETF
1.5%
VanEck Biotech ETF
1.4%
詳細を見る
First Trust NYSE Arca Biotechnology Index Fund
比率3.44%
Global X Genomics & Biotechnology ETF
比率2.98%
Invesco Biotechnology & Genome ETF
比率2.47%
First Trust Health Care Alphadex Fund
比率2.15%
Goldman Sachs Future Health Care Equity ETF
比率2.15%
State Street SPDR S&P Biotech ETF
比率1.93%
WealthTrust DBS Long Term Growth ETF
比率1.86%
Alger Russell Innovation ETF
比率1.84%
Virtus LifeSci Biotech Products ETF
比率1.5%
VanEck Biotech ETF
比率1.4%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
よくある質問
BioMarin Pharmaceutical Incの上位5名の株主は誰ですか？
BioMarin Pharmaceutical Incの上位5名の株主は以下のとおりです。
The Vanguard Group, Inc.は18.91M株を保有しており、これは全体の9.85%に相当します。
BlackRock Institutional Trust Company, N.A.は18.04M株を保有しており、これは全体の9.39%に相当します。
PRIMECAP Management Companyは15.77M株を保有しており、これは全体の8.21%に相当します。
Dodge & Coxは15.11M株を保有しており、これは全体の7.87%に相当します。
State Street Investment Management (US)は8.85M株を保有しており、これは全体の4.61%に相当します。
The Vanguard Group, Inc.は18.91M株を保有しており、これは全体の9.85%に相当します。
BlackRock Institutional Trust Company, N.A.は18.04M株を保有しており、これは全体の9.39%に相当します。
PRIMECAP Management Companyは15.77M株を保有しており、これは全体の8.21%に相当します。
Dodge & Coxは15.11M株を保有しており、これは全体の7.87%に相当します。
State Street Investment Management (US)は8.85M株を保有しており、これは全体の4.61%に相当します。
BioMarin Pharmaceutical Incの株主タイプ上位3種は何ですか？
BioMarin Pharmaceutical Incの株主タイプ上位3種は、
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
PRIMECAP Management Company
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
PRIMECAP Management Company
BioMarin Pharmaceutical Inc（BMRN）の株式を保有している機関の数はいくつですか？
2025Q4時点で、BioMarin Pharmaceutical Incの株式を保有している機関は1296社あり、保有株式の総市場価値は約187.90Mで、全体の108.82%を占めています。2025Q3と比較して、機関の持ち株は-2.31%増加しています。
BioMarin Pharmaceutical Incの最大の収益源は何ですか？
FY2025Q2において、Voxzogo部門がBioMarin Pharmaceutical Incにとって最大の収益を生み出しており、その金額は221.39Mで、全収益の27.23%を占めています。
